PROMOMED DM LLC exchange-traded bonds began circulation in the market of high-tech innovative companies

On March 4, 2021, Moscow Stock Exchange PJSC included PROMOMED DM LLC's exchange-traded bonds (MOEX: RU000A102LB5) in the listing of the Innovation and Investment Market (RII) sector. The decision was made in accordance with the Rules of the trading platform and makes the company's bonds even more attractive to a wide range of investors, exempting them from paying personal income tax on transactions with these securities.

The inclusion of exchange-traded bonds in RIA's quotation lists indicates not only the strategic importance of the issuer for the government and the pharmaceutical industry, but also the company's compliance with strict requirements for corporate governance and the quality of information disclosure.

In addition, listing on RIA automatically confirms the fact of carrying out activities using innovative technologies and approaches, as well as investments in high-tech projects. Finally, according to the rules of the trading platform, continuous possession of exchange-traded instruments from the RIA list for at least 1 year is exempt from personal income tax. This is an additional argument for investors who have decided to invest in the securities of innovative companies.

According to Andrey Mladentsev, Chief Executive Officer of PROMOMED, the company will continue to work on realizing the scientific and industrial potential to produce effective and high-quality products that preserve the health of millions of Russians. "This is what makes PROMOMED an investment-attractive company for investors interested in obtaining a stable coupon income," he explained.

The Moscow Stock Exchange was established in 2009 and is a trading platform for high-tech, innovative and dynamically developing companies. Interest-bearing non-convertible non-documentary exchange-traded bonds with collateral and centralized rights accounting of the 001P-01 series of PROMOMED DM LLC are included in the "Third level" section of the list of securities admitted to circulation on the RII.

The investment program of the PROMOMED Group of Companies is focused on the development and production of active pharmaceutical substances and ready-made dosage forms, the construction of new laboratories and workshops. In the near future, the company plans to focus on the creation of innovative antiviral, antibacterial, endocrinological and oncological drugs.